Evogene

What Evogene does

Evogene is an Israeli computational biology company headquartered in Rehovot that applies generative AI and machine learning to discover and design small molecules, microbial products, and genetic elements for life-science industries. Its core technology comprises three proprietary AI tech-engines: ChemPass AI for small-molecule design, MicroBoost AI for microbial strain optimization, and GeneRator AI for genetic element design. ChemPass AI is reported to operate against a proprietary training dataset of approximately 38-40 billion molecules and to demonstrate roughly 90% precision versus approximately 29% for GPT-based generative chemistry approaches.

The company serves two principal end markets: pharmaceutical drug discovery (via licensing and collaboration agreements with biotech firms) and agricultural biotechnology (crop protection, ag-biologicals, and seed trait development). Named commercial partners and customers include Bayer, Corteva, Shanghai Lishan Biopharmaceuticals, and ICL Group. Recent licensing activity includes an exclusive worldwide license of BMC128, an anti-inflammatory microbiome candidate, to Lishan Biotech (February 2026). The company's academic and translational collaborators include Systasy Bioscience, LMU Munich, QUT, Unravel Biosciences, and Tel Aviv University, supporting pipeline indications in multiple sclerosis, cisplatin-resistant NSCLC, neutrophil-driven inflammation, and metabolic disease.

Evogene generates revenue primarily through licensing fees, milestone payments under collaboration agreements, and limited seed-product sales. Following a 2025 strategic transformation in which it divested Lavie Bio (its ag-biological subsidiary) to ICL Group, the company has narrowed its operational focus toward its core AI platform and pharmaceutical pipeline. The company is publicly traded on Nasdaq (ticker: EVGN) and on the Tel Aviv Stock Exchange. FY2025 revenue was $3.9M (down from $5.6M in FY2024), with a net loss of $7.8M and a cash position of approximately $13.0-13.1M; the market capitalization is reported in the $4.4-7.3M range, with shares trading below $1 and an active Nasdaq listing-compliance concern.

Name

Evogene

Legal name

Evogene Ltd.

Website

https://evogene.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

251–500 employees

Short description

Evogene is an Israeli computational biology company that applies generative AI to design small molecules, microbial products, and genetic elements for pharmaceutical drug discovery and agricultural biotechnology, generating revenue through licensing fees, milestone payments, and limited seed-product sales.

Ownership category

akta.pro rank

Product category

AI-Driven Drug Discovery and Computational Chemistry

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411), Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM)

Keywords

• Generative AI drug discovery
• Computational chemistry platform
• Small molecule design
• Agricultural crop protection
• AI pharma platform

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Collaborations and Licensing - Pharmaceutical: Revenue from strategic partnerships with pharmaceutical and biotech companies for drug discovery using ChemPass AI, including milestone payments and potential royalties on successful development.
2. Collaborations and Licensing - Agricultural Chemicals: Revenue from AgPlenus subsidiary collaborations with Bayer and Corteva for novel herbicide development using ChemPass AI, including milestone payments.
3. Seed Product Sales - Casterra: Revenue from the sale of proprietary castor seeds for biofuel feedstock production, with sales agreements to African countries and Brazil. Significantly declined YoY (86% decrease in Q1 2026).
4. Licensing of Divested Assets: Revenue from licensing deals including Biomica's BMC128 licensed to Lishan Biotech (development milestones and royalties), and Lavie Bio divested to ICL Group.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Evogene develops and licenses proprietary generative AI platforms, principally ChemPass AI, for designing novel small molecules optimized across efficacy, toxicity, and stability parameters. The company applies these platforms to pharmaceutical drug discovery and agricultural crop protection, operating through wholly-owned subsidiaries (Biomica, AgPlenus, Casterra Ag) and strategic licensing collaborations with partners such as Bayer, Corteva, Google Cloud, and Lishan Biotech.

Product overview

Evogene operates as a computational chemistry company with three proprietary AI tech-engines: ChemPass AI (small molecules), MicroBoost AI (microbes), and GeneRator AI (genomic elements). These platforms power both internal product development through subsidiaries and strategic partnerships. The company serves two primary markets: pharmaceutical drug discovery (human health therapeutics) and agricultural chemicals (crop protection). Key subsidiaries include Biomica (microbiome-based therapeutics), AgPlenus (ag-chemicals), and Casterra Ag (castor seeds for biofuel). Following 2025 strategic transformation, the company divested Lavie Bio and licensed Biomica's BMC128 to focus on ChemPass AI-driven small molecule discovery.

Differentiator

Problem solved

Functional benefit

Brands

• ChemPass AI: Proprietary generative AI tech-engine for optimized multi-parameter novel small molecule design for pharmaceutical and agricultural applications
• MicroBoost AI
• GeneRator AI
• Biomica
• AgPlenus
• Casterra Ag

Products and services

• ChemPass AI Proprietary generative AI tech-engine for optimized multi-parameter novel small molecule design, enabling the creation of highly potent molecules for pharmaceutical drug discovery and agricultural ag-chemicals.
• MicroBoost AI AI computational biology platform focused on discovery and development of products based on microbes, powering Biomica's microbiome-based therapeutics and previously Lavie Bio's ag-biologicals.
• GeneRator AI AI computational platform for genomic modification and genetic element discovery, powering Casterra Ag's castor seed variety development and licensed to Finally Foods for molecular farming.
• BMC128 (LS-LBP-002) Rationally designed live bacterial therapeutic candidate developed by subsidiary Biomica to facilitate anti-tumor immune responses in patients receiving immune checkpoint inhibitors. Licensed to Lishan Biotech for renal cell carcinoma and non-small cell lung cancer.
• Biomica (Subsidiary Operations) Subsidiary developing novel microbiome-based therapeutics for human disorders, powered by MicroBoost AI platform, focused on immuno-oncology and inflammatory bowel disease.
• AgPlenus (Subsidiary Operations) Subsidiary developing next-generation ag-chemicals for effective and sustainable crop protection, powered by ChemPass AI, with active collaborations with Bayer and Corteva for novel herbicide development.
• Casterra Ag (Subsidiary Operations) Subsidiary developing and marketing superior castor seed varieties producing high yield and high-grade oil content for biofuel and other industries, powered by GeneRator AI.

Quantifiable outcome

• ~90% precision in producing novel molecules meeting all design criteria, vs ~29% for traditional GPT-based approaches
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

13 partnerships are on record, tiered core, strategic and minor.

• Google CloudcoreTechnology or Integration · 24 June 2026Expanded collaboration integrating agentic computational systems and Google's Gemini models into Evogene's ChemPass AI platform for autonomous small-molecule discovery. Leverages Google Cloud's Vertex AI platform to automate scientific workflows and enable large-scale parallel molecular exploration. This is the second major milestone following the initial collaboration in October 2024. Potential future availability through Google Cloud Marketplace.
• Queensland University of Technology (QUT)strategicStrategic or Co-development Partner · 17 February 2026Collaboration to develop AI-driven cancer therapeutics targeting chemotherapy-resistant non-small cell lung cancer (NSCLC). Combines Evogene's ChemPass AI generative molecular design platform with Dr. Mark Adams' research on a novel cellular pathway driving Cisplatin resistance, which affects 60-70% of patients receiving standard chemotherapy. Aims to design small-molecule inhibitors that restore treatment sensitivity.
• Systasy Bioscience GmbHstrategicStrategic or Co-development Partner · 11 February 2026International collaboration backed by a EUREKA grant to develop targeted small-molecule therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease. Evogene leads AI-powered molecule discovery using ChemPass AI; Systasy contributes its PathwayProfiler DNA barcoding platform for multiplexed profiling of stem cell-derived neutrophils. Weizmann Institute provides computational design integration.
• LMU University Hospital MunichstrategicStrategic or Co-development Partner · 11 February 2026Partnership with Systasy and Evogene to develop neutrophil-derived inflammatory disease therapies, supported by a pan-European EUREKA grant. LMU's Dr. von Hauner Children's Hospital provides clinical validation by validating lead compounds in human in vitro neutrophil models. Based on clinical insights from a rare genetic immunodeficiency identifying a novel inborn error of immunity associated with reduced neutrophil numbers.
• Shanghai Lishan Biopharmaceuticals Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 4 February 2026Exclusive worldwide licensing agreement for BMC128 (designated LS-LBP-002), Biomica's first-in-class microbiome-based therapeutic for renal cell carcinoma and non-small cell lung cancer. Lishan assumes responsibility for global clinical development, manufacturing, and commercialization. Biomica receives development milestone payments and royalties on future commercial sales. Lishan plans Phase 2 clinical study and regulatory filings in China and the US.
• Unravel Biosciences, Inc.strategicStrategic or Co-development Partner · 7 January 2026Scientific collaboration to jointly develop a first-in-class small-molecule therapeutic capable of restoring myelin and reversing neurological damage in demyelinating diseases such as Multiple Sclerosis. Combines Evogene's ChemPass AI generative chemistry platform with Unravel's BioNAV predictive biology platform and patient-derived Living Molecular Twins technology. No approved therapy currently exists to effectively reverse myelin loss.
• Professor Ehud Gazit of Tel Aviv UniversitystrategicStrategic or Co-development Partner · 12 August 2025Scientific collaboration with Tel Aviv University's Professor Ehud Gazit, a world leader in molecular self-assembly, facilitated by Ramot tech transfer company. Aims to discover and optimize novel small molecules as drug candidates for diseases caused by ordered self-assembly of small metabolites, including Tyrosinemia, Gout, and Maple Syrup Urine Disease (MSUD). Combines Evogene's ChemPass AI with Professor Gazit's expertise in characterizing and manipulating self-organization of biological molecules.
• Bayer AGcoreStrategic or Co-development PartnerLicensing and collaboration agreement between AgPlenus and Bayer to develop new sustainable weed control solutions, leveraging Bayer's CropKey approach to crop protection innovation. The collaboration was terminated in 2025 after the target protein failed to meet product criteria, with assets reverting to AgPlenus.
• Corteva AgrisciencecoreStrategic or Co-development PartnerCollaboration with AgPlenus for development of novel herbicides. Corteva also invested in Lavie Bio and signed a licensing agreement for Lavie Bio's bio-fungicides. AgPlenus achieved milestones in this collaboration for novel herbicide development.
• Weizmann Institute of ScienceminorStrategic or Co-development PartnerParticipates in the EUREKA-backed neutrophil drug discovery collaboration alongside Evogene and Systasy, providing computational design integration and experimental validation support.
• Finally Foods Ltd.minorOEM/ Whitelabel/ Licensing PartnerMolecular farming startup using Evogene's GeneRator AI technology under exclusive license to produce dairy proteins in potatoes. First molecular farming startup to express all four casein sub-units within a single organism. Targeting USDA and FDA regulatory filings in 2027.
• Fantini s.r.lminorChannel Partner/ Reseller/ DistributorPartnership with Casterra to advance agricultural mechanization for scalable commercial castor farming, supporting mechanized harvesting solutions for castor bean production in Brazil.
• ICL Group Ltd.coreOEM/ Whitelabel/ Licensing PartnerAcquired the activity of Lavie Bio, Evogene's agricultural biologicals subsidiary, as part of Evogene's strategic transformation to focus on ChemPass AI. ICL and Lavie Bio had previously collaborated on developing yield-increasing bio-stimulants using AI. Lavie Bio was sold to ICL as part of non-core asset divestment.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Emerging players

• Isomorphic Labs: Alphabet-backed AI drug discovery company spun out of DeepMind, focused on computational small-molecule design. A well-capitalized next-generation competitor in the same generative chemistry space as ChemPass AI, leveraging the same Google Cloud / Vertex AI infrastructure.
• Benevolent AI: AI-driven drug discovery company applying knowledge graphs and machine learning to identify novel targets and small molecules. Operates in the same AI-pharma-discovery category as Evogene with comparable B2B partnership model.

Direct peers

• Schrödinger, Inc. Computational chemistry and molecular simulation platform serving pharma and materials science customers. Directly comparable to Evogene's ChemPass AI on the small-molecule design and multi-parameter optimization axis, with Schrödinger historically referenced in Evogene's own user-group presentations.
• Atomwise: AI-driven small-molecule drug discovery company using deep learning to predict binding and design novel compounds. A direct competitor to Evogene's ChemPass AI in generative chemistry for pharma collaborations.
• Insitro: Machine learning-driven drug discovery platform combining high-throughput biology and computational models to build predictive disease models. Competes with Evogene in AI-enabled small-molecule and target discovery for pharma partners.
• XtalPi: AI- and quantum-physics-driven drug discovery company offering small-molecule design and prediction services to pharma partners globally. Directly comparable in business model (B2B AI-driven small-molecule discovery) and in serving both pharma and ag-chemical-style end markets.
• InSilico Medicine: AI-driven drug discovery and aging research company with end-to-end generative chemistry and target identification capabilities. Comparable to Evogene in operating an AI-first pharma pipeline plus B2B partnerships.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Comparable to Evogene's AI-first small molecule discovery approach targeting pharma partnerships and pipeline development.

Broad incumbents

• Bayer AG (Crop Science): Global life-sciences incumbent with a major Crop Science division. A relevant comparator as a large established player in agricultural chemicals that Evogene's AgPlenus subsidiary has partnered with (and lost) for novel herbicide discovery — the industry target customer and the incumbent Evogene is helping disrupt.
• Corteva Agriscience: Global pure-play agriculture company and a major crop protection player. Comparable both as the incumbent competitor in the herbicide market Evogene is targeting and as an active partner on the AgPlenus collaboration for novel herbicide chemistry.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/evogene_ltd
• Facebookfacebook.com/evogene.careers
• LinkedInlinkedin.com/company/evogene

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds10 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evogene